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The sarcoplasmic reticulum (SR) calcium homeostasis is due to a
dynamic balance between the capture of the cytosolic calcium by calcium
pumps such as SERCA (Sarco Endoplasmic Reticulum Calcium ATPase)
and calcium release, actively across calcium channels such as IP3 (Inositol
Tri-phosphate) and ryanodine receptors, or passively via calcium leak
channels.
Few data are available concerning the functional characterization of
leak channels in the SR. These channels are involved in the regulation of
the reticular calcium concentration as well as in the exchange of calcium
between SR and other intracellular organelles. Therefore, their character-
ization is important for a better understanding of the physiology of the
cells.
Recently, we have demonstrated that TRPV1 (Transient Receptor Potential
Vanilloid 1), a cationic channel, is a functional calcium leak channel on the
SR of mouse skeletal muscle cells. TRPV1 is activated by acidosis, high
temperature (>42°C), and by pharmacological molecules such as capsaicin,
resiniferatoxin and capsazepin.
We are pursuing our investigation of these channels in C57Bl6 mouse car-
diomyocytes.
Our preliminary results show that TRPV1 is active in mice cardiomyocytes
as a calcium leak channel after stimulation or inhibition using pharmaco-
logical molecules.
These data were confirmed by using a genetic approach: the C57Bl6 KO
mice for TRPV1 channel.
Lately, reducing cardiac injuries after ischemia reperfusion where calcium
dynamics play a crucial role became a major interest. Therefore, the modula-
tion of the TRPV1 calcium leak channel might be a new approach in cardio-
protection.
0227
Mineralocorticoid receptor deficiency in smooth muscle cells protects
against renal injury induced by ischemia/reperfusion
Jonatan Barrera-Chimal (1), Sonia Prince (1), Fouad Fadel (1), Alan Le
Mercier (1), Soumaya El Moghrabi (1), Norma Bobadilla (2), Frederic
Jaisser (1)
(1) Centre de Recherche des Cordeliers, INSERM U1138 Team 1, Paris,
France – (2) Instituto de Investigaciones Biomedicas, Molecular Physio-
logy, UNAM and INNSZ, Mexico City, Mexique
Introduction: Renal ischemia/reperfusion (IR) is an important cause of
acute kidney injury (AKI). AKI has been linked with progression to chronic
kidney disease and development of cardiac alterations. Previous studies from
our laboratory have shown that mineralocorticoid receptor (MR) antagonism
with spironolactone prevents tubular injury and renal dysfunction induced by
IR. The protection mechanisms remain unclear and whether the blockade of
vascular MR is responsible for the protection conferred by MR antagonists in
IR remains unexplored.
Objective: To evaluate the specific contribution of vascular MR in the
development of the kidney injury induced by IR.
Methods: To investigate the contribution of vascular MR we generated
two knockout (KO) mouse models. To allow MR inactivation in endothelial
cells (MRendoKO mice), floxed MR mice (MRfl/fl) were crossed with mice
expressing the Cre recombinase under the Tie2cre promoter. To allow MR
inactivation in smooth muscle cells (MRSMCKO mice), MRfl/fl mice were
crossed with mice expressing the inducible Cre recombinase under the SMA
promoter (MRSMCKO). In these mice, sham surgery or bilateral renal IR for
20min was performed. The animals were studied 24h after reperfusion. As
markers of tubular injury, the mRNA levels of Kim-1 and NGAL were
quantified.
Results: In MRfl/fl mice, IR induced renal dysfunction (plasma creatinine
raised from 8.9±0.3 in sham to 33.8±4.8 μmol/L in IR), tubular injury and an
increase in mRNA levels of Kim-1 (400-fold) and NGAL (200-fold). The
MRendoKO mice displayed similar alterations induced by IR as MRfl/fl mice. In
contrast, after renal IR, the MRSMCKO mice presented normal renal function
(plasma creatinine was 9.6±0.7 and 14.0±1.9 μmol/L in sham and IR, respec-
tively), absence of histological alterations and a significant reduction in the
mRNA levels of Kim-1 and NGAL. We are now testing the effect of MR
deficiency in smooth muscle cells in preventing the development of chronic
alterations induced by IR.
Conclusion: We show that the deficiency of the MR expressed in smooth
muscle cells protects against the renal injury induced by IR. Our data provides
further evidence to support the use MR antagonists as a novel therapeutic
approach to prevent acute and chronic consequences of renal IR.
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Background: Acute myocardial infarction (AMI) is a major cause of
mortality worldwide. Early reperfusion is the only treatment recommended
to reduce infarct size. However, reperfusion induces also deleterious
secondary effects called ischemia-reperfusion (IR) injury due to irreversible
apoptotic death of cardiomyocytes. Most ischemic episodes are triggered by
an increase in heart rate that induces an imbalance between myocardial
oxygen delivery and consumption. The BEAUTIFUL clinical trial has
demonstrated that moderate heart rate reduction diminishes the frequency of
AMI episodes in patients with stable coronary artery disease having
increased heart rate at rest. The HCN-mediated If current and the Cav1.3-
mediated L-type Ca2+ currents play important roles in the generation of auto-
maticity and heart rate, therefore they are interesting targets for selective
control of heart rate and cardioprotection during AMI. The aim of this study
was to investigate if Cav1.3 channels could be a putative target to reduce
infarct size.
Methods: Anesthetized C57BL/6J, Cav1.3-/- and Girk4-/- mice were sub-
jected to a surgical protocol of myocardial IR (40min ischemia-60 min reper-
fusion). Heart rate was measured with a one-lead surface ECG recording, and
infarct size with triphenyl tetrazolium chloride staining.
Results: Selective heart rate decrease (26%) in an in vivo mouse model of
AMI is associated with reduced IR injury. Ivabradine administration before
ischemia significantly reduced infarct size (–33%). Cav1.3-/- mice presented
reduced infarct size (–30%) compared to WT mice. In addition, Girk4-/- mice,
a genetic model of moderate tachycardia (10%) displayed increased infarct
size (+30%) compared to control mice.
Conclusions: These results show a direct relationship between heart rate
and IR injury. Heart rate reduction by inhibition of Cav1.3 channels constitutes
a promising strategy to reduce infarct size.
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